DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Citigroup Initiates Coverage On Prevail Therapeutics with Buy Rating, Announces $24 Price Target

Citigroup analyst Neena Bitritto-Garg initiates coverage on Prevail Therapeutics (NASDAQ:PRVL) with a Buy rating and a $24 price target.

Benzinga · 03/06/2020 10:07

Citigroup analyst Neena Bitritto-Garg initiates coverage on Prevail Therapeutics (NASDAQ:PRVL) with a Buy rating and a $24 price target.